Back to Browse Journals » Clinical Interventions in Aging » Volume 4

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia

Authors Dhiren Singh, Daniel W O’Connor

Published Date August 2009 Volume 2009:4 Pages 351—355

DOI http://dx.doi.org/10.2147/CIA.S3252

Published 26 August 2009

Dhiren Singh1,2, Daniel W O’Connor1

1Department of Psychological Medicine, Monash University, Melbourne, Australia; 2Peninsula Mental Health Service, Melbourne, Australia

Abstract: Antipsychotic medication is the mainstay of treatment in elderly patients with psychosis. In recent years, second generation antipsychotics have come to be preferred. Longacting risperidone is the first such antipsychotic available for use in this vulnerable group of patients and offers an attractive alternative to traditional medications. The available literature revealed that long-acting risperidone is generally well tolerated and is effective in treating both the positive and negative symptoms of schizophrenia. Despite a lack of randomized trials and head-to-head studies, it appears to be a useful addition to the treatment armory for patients with chronic psychosis who require a depot preparation. Further research into its endocrine and metabolic side effects is needed.

Keywords: risperidone, long-acting injection, old age, efficacy, safety

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read: